Kurzfassung

A prospective phase I/IIa, open-label, multicenter trial to evaluate the safety and efficacy of oNKord, an off-the-shelf, ex-vivo-cultured allogeneic NK cell preparation , in subjects with acute myeloid leukemia who are in morphologic complete remission with measurable residual disease and who are currently not proceeding to allogeneic hematopoietic stem cell transplantation.